Was ist die Webseite?

Metys Pharmaceuticals AG

Startseite
Schweiz
Basel
Metys Pharmaceuticals AG

Seeking investors to develop dimiracetam for prevention of oxaliplatin-induced symptoms of neurotoxicity. World-wide granted patents protect its use.

Metys Pharmaceuticals is a Swiss start-up company developing dimiracetam, a Phase II-ready, orally active small molecule, for prevention of cancer chemotherapy-induced symptoms of neurotoxicity. We seek additional investors to join the $16 million Series A round which will mainly fund the DISTALL trial, a randomized, placebo-controlled, double-blind, parallel group dose-ranging study of dimiraceta

m for prevention of oxaliplatin-induced symptoms. Financial prospects for investors are highly lucrative: liquidation preferences, dividends, anti-dilution measures, and a $10 million pre-money valuation are agreed with current prospective Swiss Series A investors. Exit is foreseen within 2.5-3.5 years; recent comparable deals paid $200+ million upfront + milestones. Dimiracetam blocks glutamate-induced glutamate release in the spinal cord, the basis for the persistent pain signalling; it is effective in numerous rat models chemotherapy-induced neuropathic pain. The DISTALL trial has been designed with world-leading oncologists and neurologists; it will be conducted in the US.

Adresse

Basel
4051BASEL

Webseite

http://metys-pharma.ch/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Metys Pharmaceuticals AG erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.